REGENXBIO Inc. (RGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
9.49 USD
+0.30
(3.264%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 9.70 +0.21 (2.211%) ⇧ (April 17, 2026, 5:49 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:30 p.m. EDT
RGNX is a high-risk, high-reward stock with a significant short-term volatility. The recent price movements show a lack of clear direction, with frequent fluctuations. The stock's fundamentals are weak, with negative earnings and a high debt-to-equity ratio, making it unsuitable for long-term investment. The options market is mixed, with both bullish and bearish bets, but the overall sentiment is not strongly aligned. Investors should be cautious and consider the high risk before entering any position. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.401755 |
| MSTL | 0.425593 |
| AutoTheta | 0.524413 |
| AutoARIMA | 0.645552 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 71% |
| H-stat | 1.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.053 |
| Excess Kurtosis | -0.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 253.587 |
| Revenue per Share | 3.305 |
| Market Cap | 489,847,520 |
| Forward P/E | -4.32 |
| Beta | 1.13 |
| Profit Margins | -113.75% |
| Website | https://www.regenxbio.com |
As of April 11, 2026, 3:30 p.m. EDT: Options activity shows mixed signals. Calls have significant open interest and volume at strikes above the current price, indicating potential bullish sentiment for higher prices. However, puts also show substantial open interest at lower strikes, suggesting some bearish positioning. The IV is relatively low across expirations, which might indicate a lack of conviction or volatility expectations. The ATM strikes are heavily traded, which could signal a focus on the current price range. Overall, the options market appears to be cautious, with both bullish and bearish bets present.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.37781107 |
| Address1 | 9,804 Medical Center Drive |
| All Time High | 85.1 |
| All Time Low | 5.035 |
| Ask | 9.67 |
| Ask Size | 5 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 541,550 |
| Average Daily Volume3 Month | 958,111 |
| Average Volume | 958,111 |
| Average Volume10Days | 541,550 |
| Beta | 1.134 |
| Bid | 9.3 |
| Bid Size | 5 |
| Board Risk | 8 |
| Book Value | 2.019 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.49 |
| Current Ratio | 2.382 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.62 |
| Day Low | 9.28 |
| Debt To Equity | 253.587 |
| Display Name | REGENXBIO |
| Earnings Call Timestamp End | 1,772,715,600 |
| Earnings Call Timestamp Start | 1,772,715,600 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda | -145,583,008 |
| Ebitda Margins | -0.85415 |
| Enterprise To Ebitda | -3.574 |
| Enterprise To Revenue | 3.052 |
| Enterprise Value | 520,255,232 |
| Eps Current Year | -1.99875 |
| Eps Forward | -2.196 |
| Eps Trailing Twelve Months | -3.76 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.779 |
| Fifty Day Average Change | 0.7109995 |
| Fifty Day Average Change Percent | 0.08098866 |
| Fifty Two Week Change Percent | 37.78111 |
| Fifty Two Week High | 16.19 |
| Fifty Two Week High Change | -6.700001 |
| Fifty Two Week High Change Percent | -0.41383573 |
| Fifty Two Week Low | 5.85 |
| Fifty Two Week Low Change | 3.6399999 |
| Fifty Two Week Low Change Percent | 0.6222222 |
| Fifty Two Week Range | 5.85 - 16.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,496,600,000 |
| Float Shares | 42,998,261 |
| Forward Eps | -2.196 |
| Forward P E | -4.321493 |
| Free Cashflow | -79,794,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 371 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -0.45855 |
| Gross Profits | -78,156,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.078200005 |
| Held Percent Institutions | 0.81122 |
| Implied Shares Outstanding | 51,617,233 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. |
| Long Name | REGENXBIO Inc. |
| Market | us_market |
| Market Cap | 489,847,520 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_130641748 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -193,878,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 489,847,541 |
| Number Of Analyst Opinions | 11 |
| Open | 9.485 |
| Operating Cashflow | -123,963,000 |
| Operating Margins | -1.8998599 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 240 552 8181 |
| Post Market Change | 0.20979977 |
| Post Market Change Percent | 2.2107458 |
| Post Market Price | 9.6998 |
| Post Market Time | 1,776,462,542 |
| Previous Close | 9.19 |
| Price Eps Current Year | -4.7479672 |
| Price Hint | 2 |
| Price To Book | 4.7003465 |
| Price To Sales Trailing12 Months | 2.8740005 |
| Profit Margins | -1.13751 |
| Quick Ratio | 2.272 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.54545 |
| Region | US |
| Regular Market Change | 0.3 |
| Regular Market Change Percent | 3.26442 |
| Regular Market Day High | 9.62 |
| Regular Market Day Low | 9.28 |
| Regular Market Day Range | 9.28 - 9.62 |
| Regular Market Open | 9.485 |
| Regular Market Previous Close | 9.19 |
| Regular Market Price | 9.49 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 434,784 |
| Return On Assets | -0.21925 |
| Return On Equity | -1.07001 |
| Revenue Growth | 0.43 |
| Revenue Per Share | 3.305 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 51,617,233 |
| Shares Percent Shares Out | 0.13 |
| Shares Short | 6,710,934 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,386,587 |
| Short Name | REGENXBIO Inc. |
| Short Percent Of Float | 0.15720001 |
| Short Ratio | 6.91 |
| Source Interval | 15 |
| State | MD |
| Symbol | RGNX |
| Target High Price | 50.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 27.81818 |
| Target Median Price | 27.0 |
| Total Cash | 230,070,000 |
| Total Cash Per Share | 4.458 |
| Total Debt | 260,518,000 |
| Total Revenue | 170,440,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.513225 |
| Two Hundred Day Average Change | -1.0232248 |
| Two Hundred Day Average Change Percent | -0.0973274 |
| Type Disp | Equity |
| Volume | 434,784 |
| Website | https://www.regenxbio.com |
| Zip | 20,850 |